Menu Search
Equities

Evome Medical Technologies Inc

EVMT:CVE

Evome Medical Technologies Inc

Actions
  • Price (CAD)0.14
  • Today's Change0.01 / 7.69%
  • Shares traded42.00k
  • 1 Year change-33.33%
  • Beta1.3546
Data delayed at least 15 minutes, as of Nov 14 2024 19:45 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CADIncome statement in CADView more

Year on year Evome Medical Technologies Inc grew revenues 86.42% from 33.59m to 62.63m while net income improved from a loss of 15.90m to a smaller loss of 15.60m.
Gross margin34.58%
Net profit margin-33.45%
Operating margin-36.25%
Return on assets-35.78%
Return on equity-289.79%
Return on investment-144.36%
More ▼

Cash flow in CADView more

In 2023, cash reserves at Evome Medical Technologies Inc fell by 1.01m. Cash Flow from Financing totalled 824.54k or 1.32% of revenues. In addition the company used 918.91k for operations while cash used for investing totalled 1.52m.
Cash flow per share-0.1722
Price/Cash flow per share--
Book value per share-0.0279
Tangible book value per share-0.119
More ▼

Balance sheet in CADView more

Evome Medical Technologies Inc has a Debt to Total Capital ratio of 114.35%, a higher figure than the previous year's 53.54%.
Current ratio0.5486
Quick ratio0.2596
Total debt/total equity--
Total debt/total capital1.14
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.